Core Viewpoint - Fuxiang Pharmaceutical has obtained the GMP certification from Brazil's National Health Surveillance Agency (ANVISA) for its chemical raw material, Tazobactam, enabling the company to enter the Brazilian market and expand its international presence [1] Group 1 - The certification scope includes the chemical raw material drug Tazobactam [1] - Brazil is the largest country in South America, making this certification significant for market entry [1] - The successful certification lays a solid foundation for further expansion into the Brazilian market and other international markets, enhancing the company's global competitiveness [1]

Core Viewpoint - The company, Fuxiang Pharmaceutical, has received GMP certification from Brazil's National Health Surveillance Agency (ANVISA) for the production of the chemical raw material, Tazobactam [1] Group 1 - The certification indicates compliance with international quality management standards for pharmaceutical production [1] - The scope of the certification specifically covers the chemical raw material Tazobactam, which is significant for the company's product portfolio [1]

Core Viewpoint - Fuxiang Pharmaceutical has obtained the GMP certification from Brazil's National Health Surveillance Agency (ANVISA) for its chemical raw material, Tazobactam, enabling the company to enter the Brazilian market and expand its international presence [1] Group 1 - The certification scope includes the chemical raw material drug Tazobactam [1] - Brazil is the largest country in South America, making this certification significant for market entry [1] - The successful certification lays a solid foundation for further expansion into the Brazilian market and other international markets, enhancing the company's global competitiveness [1]

Core Viewpoint - Fuxiang Pharmaceutical has obtained the GMP certification from the Brazilian National Health Surveillance Agency (ANVISA) for the production of the chemical raw material, Tazobactam [1] Group 1 - The certification signifies compliance with international quality management standards for pharmaceutical production [1] - The scope of the certification specifically covers the chemical raw material Tazobactam, indicating a focus on this product line [1]

Core Viewpoint - Fuxiang Pharmaceutical has obtained GMP certification from the Brazilian National Health Surveillance Agency for its chemical raw material, Tazobactam, enabling the product's entry into the Brazilian market and laying the groundwork for further international market expansion [1] Summary by Categories - **Certification Achievement** - The company received GMP certification for Tazobactam, which is a significant milestone for its international operations [1] - **Market Expansion** - This certification allows the company to enter the Brazilian market, indicating potential growth opportunities in South America [1] - **Business Risks** - The international raw material pharmaceutical business is subject to various influencing factors, which introduces uncertainty [1]

江西富祥药业股份有限公司 证券代码：300497 证券简称：富祥药业 公告编号：2025-072 由于医药产品的行业特点，国际原料药业务易受国家政策、海外市场环境变化、 供求关系等因素影响，具有一定的不确定性，敬请广大投资者谨慎决策，注意投资风 险。 特此公告。 关于公司通过巴西国家卫生监督局GMP认证的公告 近日，江西富祥药业股份有限公司（以下简称"公司"）取得了由巴西国家卫生 监督局（ANVISA）签发的药品生产质量管理规范（GMP）认证证书。认证范围为化 学原料药：他唑巴坦。具体情况如下： 一、证书基本信息 生产商：江西富祥药业股份有限公司 二、对公司的影响及风险提示 巴西是南美洲最大的国家，本次公司他唑巴坦顺利通过巴西国家卫生监督局的 GMP认证，为公司的他唑巴坦产品成功进入巴西市场创造了条件，对其进一步拓展巴 西市场和其他国际市场奠定坚实基础，有利于提升公司的国际竞争力。 公司地址：江西省景德镇市昌江区鱼丽工业区2号，333000 认证编号：0445875/23-2 认证范围：化学原料药：他唑巴坦 决议日期：2025年9月25日 有效期限：2027年9月30日 发证机关：巴西国家卫生监督局（ANVI ...

Core Viewpoint - The surge in lithium hexafluorophosphate prices has led to increased institutional research on companies in the supply chain, particularly those producing vinylene carbonate (VC), a key additive for lithium battery electrolytes [1][2]. Group 1: Company Developments - Yongtai Technology has reported a current production capacity of 5,000 tons/year for VC, with an additional 5,000 tons/year capacity entering trial production as of November 17, bringing total capacity to 10,000 tons/year [1]. - Fuxiang Pharmaceutical plans to increase its VC production capacity from 8,000 tons/year to 10,000 tons/year through technological upgrades, expected to be completed by Q2 2026 [1]. - Lianhong Xinke is in trial production for its 4,000 tons/year VC facility and is recognized as a major supplier of lithium battery electrolyte solvents [1]. Group 2: Market Trends - VC is primarily used in lithium battery electrolytes as an organic film-forming additive and overcharge protection additive, enhancing battery efficiency and lifespan [2]. - The average market price for VC has risen to 60,000 yuan/ton, reflecting a more than 30% increase from its lowest point, with some top manufacturers experiencing inventory shortages and offering prices exceeding 70,000 yuan [2]. - The significant price increase of lithium hexafluorophosphate has positively impacted the market interest in VC, with related stocks like Fuxiang Pharmaceutical and Yongtai Technology seeing substantial gains [2]. Group 3: Production Challenges - Taihe Technology's VC project has faced delays due to land restrictions affecting the production of high-purity CEC raw materials, necessitating a redesign of production processes and the acquisition of new equipment [3]. - Yongtai Technology has indicated that its new VC production capacity is expected to ramp up quickly, within 1-2 months, due to its established production technology and management experience [3]. Group 4: Price Outlook - Yongtai Technology anticipates a continued tight balance between supply and demand for lithium battery materials, driven by the long-term growth of the new energy sector and cautious expansion in production capacity [4]. - The future price trends for lithium battery materials are influenced by multiple factors, including market supply and demand, raw material costs, and industry policies, leading to uncertainties in accurate predictions [4].

Group 1 - The organic silicon sector experienced a decline of 6.57%, ranking among the top losers in the concept sector, with stocks like Morning Light New Materials and ST Hongda hitting the limit down [1] - Major stocks in the organic silicon sector that saw significant declines include Tian Ci Materials (-9.97%), Fu Xiang Pharmaceutical (-14.29%), and Xingfa Group (-4.26%) [2] - The sector faced a net outflow of 2.285 billion yuan from main funds, with Tian Ci Materials leading the outflow at 778 million yuan [1][2] Group 2 - Among the stocks with net inflows, Gao Meng New Materials and Yuan Xiang New Materials saw inflows of 47.68 million yuan and 5.31 million yuan, respectively [1][2] - The top gainers in the organic silicon sector included Gao Meng New Materials (+9.32%) and He Yuan Gas (+3.16%) [1] - The trading volume for stocks in the organic silicon sector showed significant turnover rates, with Fu Xiang Pharmaceutical at 28.49% and Tian Ci Materials at 10.81% [2]

Market Overview - As of November 21, the Shanghai Composite Index closed at 3834.89 points, down 96.16 points, a decline of 2.45% [1] - The Shenzhen Component Index closed at 12538.07 points, down 442.75 points, a decline of 3.41% [1] - The ChiNext Index closed at 2920.08 points, down 122.26 points, a decline of 4.02% [1] Trading Activity - A total of 91 A-shares had a turnover rate exceeding 20% on this day [1] - Notable stocks with high turnover rates included: - Dapeng Industrial (920091) with a turnover rate of 98.28% and a price increase of 1211.11% [1] - Jianglong Shipbuilding (300589) with a turnover rate of 55.14% and a price increase of 14.50% [1] - C Nanshan Data (301638) with a turnover rate of 52.72% and a price increase of 0.91% [1] Notable Stocks - Other significant stocks with high turnover rates included: - C Hengkun (688727) with a turnover rate of 46.22% and a price decrease of 11.47% [1] - Inspur Software (600756) with a turnover rate of 46.20% and a price increase of 6.76% [1] - ST Dongtong (300379) with a turnover rate of 44.50% and a price increase of 4.15% [1] - Additional stocks with notable performance included: - Shennong Agriculture (300189) with a turnover rate of 42.82% and a price increase of 3.67% [1] - Beifang Changlong (301357) with a turnover rate of 42.52% and a price increase of 0.68% [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000566 | 海南海药 | 8.38 | 5.81% | 399.60万 | | 34.45 Z | | 600200 | *ST苏吴 | 1.12 | 4.67% | 67.18万 | | 7354.24万 | | 000739 | 普洛药业 | 15.84 | 1.41% | 17.06万 | | 2.71亿 | | 688117 | 圣诺生物 | 38.09 | 1.17% | - 3.35万 | | 1.25亿 | | 688506 | 百利天恒 | 374.66 | -0.11% | 8452.29 | | 3.17亿 | | 688578 | 艾力斯 | 95.49 | -0.12% | 3.69万 | | 3.54亿 | | 003020 | 立方制药 | 27.67 | -0.65% | 4.31万 | | 1.19亿 | | 002653 | 海温泉 | 56.19 | -0.86% | 3.98万 | | 2 ...